Dr. Manier Discusses Initial Data From MajesTEC-7 Phase III Trial at EHA 2024

Salomon Manier, MD, PhD, Associate Professor of Hematology at Lille University Hospital in France, spoke to Blood Cancers Today of the safety run-in results for cohort one of the phase III MajesTEC-7 study. These results were presented at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain.

These particular data from MajesTEC-7 demonstrated that the combination of teclistamab, daratumumab, and lenalidomide for multiple myeloma has promising safety and efficacy in elderly patients ineligible for autologous hematopoietic stem cell transplantation. Dr. Manier expressed encouragement from such findings as the study enters its three-arm randomized phase.